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INVESTIGATING HOST VERSUS DONOR T CELL CHIMERISM IN 
CUTANEOUS GRAFT VERSUS HOST DISEASE 
LAILA KHATIB 
ABSTRACT 
BACKGROUND: Graft versus host disease (GVHD) is a significant cause of 
morbidity and mortality following stem cell transplantation. Donor T cells are 
thought to be the main mediators of this disease, although we have recently 
identified that host T cells are present and active during acute GVHD suggesting 
contributions from both donor and host T cells. Whether both donor and host T 
cells can survive GVHD and coexist harmoniously after disease resolves is 
unknown. 
OBJECTIVE: The goals of this thesis are two-fold: (i) to study T cell chimerism in 
post-GVHD skin and (ii) to understand what effect, if any, treatment has on T cell 
chimerism in skin.     
METHODS: Acute GVHD and post-GVHD skin samples were obtained from 
male patients that had been transplanted with female donor cells. Chimerism was 
assessed using fluorescence in situ hybridization for the X and Y chromosomes 
concurrently with immunofluorescence staining for CD3, a T cell marker. 
Regulatory T cells were stained by immunofluorescence for CD3, CD4 and 
Foxp3. Medical record data was collected for all patients.     
RESULTS: We found that the percent of host T cells decreased significantly after 
resolution of acute skin GVHD compared to during active acute skin GVHD in 
 
 vi
skin samples obtained from five male patients that had been transplanted with 
female donor cells. The T cell composition in these patients in post-GVHD skin 
was primarily donor. We identified chimerism shifted toward donor T cells in 
patients treated with systemic steroids and this correlated with an increased 
number of donor T cells infiltrating into skin rather than a decrease in the number 
of host T cells in skin. With regard to frequency of Tregs, there was no significant 
difference between the group that had been treated with systemic steroids prior 
to biopsy and the group that had not.    
CONCLUSIONS: We discovered that donor chimerism predominates in post-
GVHD skin and in active skin GVHD of patients who received systemic steroids, 
suggesting a role of donor cells in acute GVHD resolution. We were not able to 
identify a higher frequency of regulatory T cells in the treatment group. It is 
possible that the Treg recruited to skin by steroid treatment is Foxp3 negative, 
and therefore missed by our staining approach. The use of another marker is 
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 Graft versus host disease (GVHD) is a major complication and cause of 
morbidity and mortality among patients who receive allogeneic hematopoietic 
stem cell transplantation (HSCT). It is a severe reaction thought to occur when 
donor T cells mount an immune response against the immunocompromised host, 
causing a reaction in various organs such as the skin, liver, lungs, and 
gastrointestinal (GI) tract (Ferrara 2009). The incidence and severity of GVHD is 
directly associated with the level of human leukocyte antigen (HLA) mismatch 
between the donor and recipient (Atkinson 1990; Loiseau 2007). However even 
of the HLA-matched HSCTs, about forty percent of recipients develop systemic 
acute GVHD, requiring treatment with high dose steroids (Ferrara 2009). Thus 
both HLA and non-HLA factors play a role in the development of GVHD. While it 
has been widely believed that donor T cells mediate GVHD, Divito et al recently 
identified the presence of a substantial population of activated host T cells in skin 
and gut during acute GVHD, suggesting a possible contribution of host T cells to 
disease (Divito 2020, Accepted for Publication). This interesting dichotomy 
between host and donor T cells in the pathogenesis and resolution of GVHD 
requires further investigation.   
 
Clinical features of acute and chronic GVHD 
 Historically, acute GVHD was classified as GVHD that occurs within the 
first one hundred days following transplant. However, recently the National 
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Institute of Health (NIH) proposed a new GVHD classification. Their definition 
includes cases of acute GVHD occurring within one hundred days of 
transplantation or persistent, recurrent or late acute GVHD that occurs after one 
hundred days. There is also an overlap syndrome (includes features of both 
acute and chronic GVHD) (Filipovich 2005; Griffith 2008; Jagasia 2015). Acute 
GVHD primarily affects the skin but also affects the GI tract, liver, lungs and can 
extend to the eyes, mouth and genitals. A characteristic feature of acute GVHD 
in the skin is a pruritic maculopapular rash. Pathologically, apoptosis at the base 
of the epidermis is characteristic. Other findings are dyskeratosis, exocytosis of 
lymphocytes, satellitosis (lymphocytes adjacent to dyskeratotic epidermal 
keratinocytes), and perivascular lymphocytic infiltration of the dermis (Ferrara 
2009; Jamil 2015). GI tract involvement of acute GVHD typically presents as 
diarrhea but can also include vomiting, anorexia, abdominal pain, or a 
combination when severe. Radiologically, luminal dilation with thickening of small 
bowel wall and air or fluid levels suggestive of ileus are found. Histological 
findings are patchy ulcerations, apoptotic bodies in the base of crypts, crypt 
abscesses, and loss and flattening of surface epithelium (Ferrara 2009). Liver 
disease caused by GVHD, like skin and gut disease caused by GVHD, is difficult 
to distinguish from other causes related to the bone marrow transplantation such 
as veno-occlusive disease, toxic drug effects, viral infection, sepsis, or iron 
overload (Ferrara 2009). Though biopsies are rarely taken due to 
thrombocytopenia in hepatic GVHD patients, histological findings would be 
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endothelialitis, lymphocytic infiltration of the portal areas, pericholangitis, and bile 
duct destruction (Choi 2005; Snover 1984). Severity of acute GVHD is staged 
according to the clinical status of the patient and extent of individual organ 
involvement, ranging from stage 1 (mild) to stage 4 (very severe), which then are 
combined to yield an overall grade (Glucksberg 1974).    
 Chronic GVHD is more autoimmune in nature- its presentation involves 
various organs such as skin, GI tract, liver, lungs, mouth, eyes, nails, female 
genitalia, muscles, fascia, joints, kidneys, marrow, and heart. Based on the NIH 
classification, the diagnosis of chronic GVHD requires at least one diagnostic 
clinical sign of chronic GVHD present such as poikiloderma or the presence of 
one distinctive manifestation such as keratoconjunctivitis sicca that is confirmed 
by a biopsy or relevant test (Filipovich 2005). Clinical signs of chronic GVHD are 
first seen in the buccal mucosa. The greatest risk factors for chronic GVHD are 
old age of recipient and history of acute GVHD. Thus, prevention strategies for 
acute GVHD are also relevant for chronic GVHD. While the focus of this thesis is 
on acute GVHD, it is important to note that there is another type of graft versus 
host disease which should be differentiated due to its separate pathogenesis and 
presentation.   
 
GVHD treatment 
 Steroids are the gold standard for treatment of acute GVHD. Topical 
steroids are usually sufficient to treat mild stages of GVHD, but in severe cases 
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systemic steroids are often administered in high doses. Extracorporeal 
photopheresis and blocking jak/stat signaling are other treatment options for 
acute GVHD. Administering immunosuppressants chronically is dangerous and 
can result in death from infection or malignancy recurrence (Ferrara 2009).  
 
Pathophysiology of GVHD 
 Acute GVHD is a severe, inflammatory process thought to be mediated by 
mature donor lymphocytes. Studies have also shown the importance of the 
microbiome and intestinal epithelium in the pathogenesis of acute GVHD (Qayed 
2016; Teshima 2016). 
The pathophysiology of acute GVHD is classically defined by three 
phases: an afferent phase, an efferent phase, and an effector phase (Ball 2008). 
In the afferent phase, activation of antigen presenting cells (APCs) occurs before 
transplant, from the underlying disease and HSCT conditioning regimen. 
Damaged host tissues respond by producing proinflammatory cytokines like 
TNF-α and IL-1 from macrophages. Activated macrophages produce chemokines 
that activate neutrophils (Zhang 2016). These proinflammatory cytokines 
increase expression of MHC and adhesion molecules on APCs, enhancing the 
APCs’ antigen-presenting capacity.  
 Donor T cells that recognize the APCs and get activated (Blazar 2012; 
Paczesny 2010) differentiate into Th1 cells and release proinflammatory 
cytokines that mediate GVHD (Carlson 2009). Th2 cells are also involved in 
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GVHD pathogenesis. Severity of GVHD is affected by the proportion of naïve 
cells maturing along Treg, Th1, Th2, or Th17 phenotypes (Henden 2015). An 
increase in secretion of proinflammatory cytokines by Th1 and Th17 cells has 
been associated with an unbalanced Treg loss (Chen 2013). Treg percentages 
and Foxp3 expression is significantly lower in severe acute GVHD patients than 
in patients without GVHD. Treg can also reduce the severity of and prevent 
GVHD in murine/rodent models. The role of Treg in GVHD resolution will be 
discussed further.  
 The second phase of GVHD is the core of the graft versus host reaction 
and is characterized by the activation of effector cells. Donor T cell activation 
further increases the expression of MHC and adhesion molecules, chemokines, 
and the expansion of host-specific cytotoxic donor CD8 T cells and CD4 T and B 
cells (Zhang 2016). 
 The effector phase involves a cascade of cellular inflammatory mediators 
(NK and cytotoxic T cells) and soluble inflammatory agents (TNF-a, interferon 
gamma, IL-1, and NO) that work together to further promote inflammation and 






Figure 1. Steps in GVHD Pathogenesis. The conditioning regimen leads to the 
damage of host tissues, leading to the release of pro-inflammatory cytokines. 
These cytokines activate host antigen presenting cells, which activate mature 
donor T cells. While the above shown mechanism is what is currently the 
widespread understanding in the literature, the mechanism shown below is that 
suggested by the discovery of Divito et al- showing that donor APCs and their 
interaction with host T cells were also found to play a role in the pathogenesis of 
disease. T cells proliferate and differentiate into Th1 and Th17 cells, which 
activate CD4 and CD8 cytotoxic T lymphocyte and natural killer cells that 
mediate tissue damage. Effector T cells along with pro-inflammatory cytokines 
migrate to and damage the target organs.  
 
T cell chimerism  
 In immunology, chimerism is defined as “the presence of two or more 
genetically distinct cell populations (from donor and recipient) in the same 

























cells has been clearly identified and defined in GVHD pathophysiology, the role 
of host T cells is less well understood. Divito et al found that T cell chimerism in 
the skin and gut, does not reflect T cell chimerism in the blood (Divito 2020, 
Accepted for Publication). Their findings showed that host T cells survive HSCT 
conditioning regimens and are present and active in the skin during acute GVHD, 
suggesting their potential role in the pathophysiology of disease. Around fifty 
percent of the T cells in skin during active acute GVHD were of host origin.   
The first experiment of this thesis will be a follow-up study of this paper 
aiming to reveal what happens to T cell chimerism in the skin after resolution of 
GVHD. Looking at the chimerism of T cells in the skin during active GVHD 
compared to post-GVHD can give us insight on the process involved in resolving 
disease.  
 
Regulatory T Cells and their role in preventing GVHD 
 Understanding the mechanisms of the cell types and subsets involved in 
GVHD may provide insight to develop better therapeutic strategies (Beres 2013). 
I will focus on regulatory T cells, based on data presented below. The primary, 
originally defined function of regulatory T cells (Treg) was to prevent autoimmune 
diseases by establishing and maintaining self-tolerance. However, various other 
functions of Treg are now recognized such that they regulate the effector phase 
of the immune response (Corthay 2009). 
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 The subsets of CD4+ regulatory T cells are natural and induced Treg cells. 
Natural Tregs develop in the thymus and upregulate Foxp3 during negative 
selection when they recognize self-antigen rather than undergoing clonal deletion 
(Beres 2013). They are responsible for maintaining immune homeostasis and 
tolerance to self antigen by inhibiting self reactive T cells in the periphery (Beres 
2013). Induced Tregs are generated when conventional T cells are activated in 
the presence of the cytokines TGF-β and IL-2, resulting in the upregulation of 
Foxp3. They can also be induced independent of TGF-β. While their role is less 
well understood, induced Tregs are thought to be important for regulating 
peripheral T cell activation during infection and mediating the contraction phase 
of the immune response. They can be generated in vitro by activating naïve T 
cells with either anti CD3 or anti CD28 antibodies in the presence of TGF-β and 
IL-2. More work needs to be done to define the precise roles and extent of these 
two Treg subsets in regulating immune responses, however a study in murine 
models has suggested that the two subsets act in a complementary fashion to 
reduce inflammation (Beres 2013).  
 While CD25 is the classical marker for regulatory T cells, Foxp3 was 
thought to be the phenotypic marker whose expression is both necessary and 
sufficient for their suppressive function. Foxp3 was thought to be essential for 
immunosuppressive Treg differentiation, and the amount of Foxp3 protein in 
Tregs to be critical for their suppressive function (Devaud 2014). Although Foxp3 
is more difficult to visualize because it is an intracellular marker and requires 
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fixation and permeabilization, this is the preferable marker for Treg (Le Texier 
2017), and so we used it in our studies for this thesis. Furthermore, CD25 is 
problematic as a marker to define Treg because it is also expressed by activated 
T effector cells (Xin Chen 2011). Newer studies have identified a unique Foxp3 
negative Treg population. This challenges the use of Foxp3 as a definitive 
marker for Treg, as not all of them express it. This will be discussed further in the 
following sections of this thesis. 
 Various studies have established a correlation between the amount of 
regulatory T cells and the risk/severity of acute GVHD. They have also 
suggested the potential for their use in therapeutics. Regulatory T cells that are 
CD4+(CD25+)Foxp3+ play a vital role in the regulatory control in graft versus 
host reactions mediated by both alloreactive and autoreactive lymphocytes and 
help to establish donor anti-host as well as self tolerance (Hess 2006). Rezvani’s 
study tells us that the Treg content of the donor graft is important in determining 
GVHD severity (Rezvani 2006). Rezvani et al quantitated the coexpression of 
Foxp3 and CD4 T cells in 32 donor stem cell transplants infused into HLA 
matched siblings and examined the incidence of GVHD in their recipients. High 
CD4+Foxp3+ T cell count in the donor was associated with a reduced risk of 
GVHD. His study also looked at regulatory T cells during immune reconstitution 
and found that a low CD4+Foxp3+ T cell count early after stem cell transplant 
(day 30) was associated with an increased risk of GVHD. The donor 
CD4+Foxp3+ T cell count was significantly higher for patients who did not 
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develop GVHD compared with patients who developed GVHD (though there was 
no significant difference between two groups of patients who had different 
severity grading of GVHD). A proportion of the CD4+Foxp3+ Treg cells were 
found to be CD25low, further emphasizing the shortcomings of CD25 as a 
marker of Treg activity. This study and its elucidation of the role of the number of 
donor Tregs in predicting GVHD has serious implications for potential treatments, 
as their manipulation can play a role in preventing or reducing the severity of 
GVHD (Rezvani 2006). 
 Regulatory T cells have been shown to suppress acute graft versus host 
disease after allogeneic bone marrow transplantation (Hoffman 2002). Hoffman 
showed that CD4+CD25+ T cells isolated from donor spleen or bone marrow are 
potent inhibitors of the acute GVHD response in mice (Hoffmann 2002). Similarly, 
many studies have identified a decreased frequency of Treg cells in the 
peripheral blood of patients with high clinical grades of acute GVHD compared to 
patients with low grade or no GVHD (Beres 2013). 
 One paper by Chen et al identified the absence of CD4+Foxp3+ regulatory 
T cells in chronic GVHD patients (Xiao Chen 2007). This study demonstrated that 
autoimmunity, which develops as a consequence of GVHD, is attributable to 
donor-derived CD4+ T cells with Th1 and Th17 cytokine phenotypes, which 
emerge as a result of the disproportionate loss of CD4+CD25+Foxp3+ cells, 
unleashing Th1 and Th17 cells to expand, thus releasing proinflammatory 
cytokines and causing pathological damage. While the topic of this thesis is not 
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chronic GVHD, this paper confirms the role of regulatory T cells in protecting 
(mice) from developing autoimmunity, and identified that acute GVHD results in 
significant reduction in the ratio between CD4+Foxp3+ to CD4+Foxp3- T cells in 
the spleen and GVHD target tissues. The implications of this, for the purpose of 
this thesis, are that during acute GVHD there is not an adequate amount of 
Foxp3+ Treg cells (thus not enough suppression), but when treated we 
hypothesize that the amount of Foxp3+ regulatory T cells increase. 
 
Impact of glucocorticosteroids on regulatory T cells 
 Glucocorticosteroids are widespread, effective drugs for transplantation 
and autoinflammatory diseases, however, the exact mechanisms of their 
immunosuppressive properties are not well understood, specifically their impact 
on Treg cells. Some studies have investigated the association between 
glucocorticosteroid treatment and enhancement of Foxp3+ regulatory T cells, 
which suppress the immune response.   
 Chen found that a glucocorticosteroid, dexamethasone, increased the 
proportion of Treg cells to T effector cells by suppressing IL-2 activation. Though 
IL-2 is important for the production of Treg cells, it is also important for the 
generation of T cell mediated immunity (Xin Chen 2006). This could be important 
therapeutically if it could be discovered how to use IL-2 to expand Treg cells 
while restraining the activation of T effector cells. Unexpectedly, they found that 
when dexamethasone was administered alone, the percentage of CD4+Foxp3+ 
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T cells actually decreased, while IL-2 treatment alone caused an increase in Treg 
percentages. When used in combination, they found that dexamethasone further 
amplified IL-2’s capacity to expand CD4+Foxp3+ T cells. They tested the effect 
of this combination on Treg cells in an experimental autoimmuno 
encephalomyelitis (EAE) murine model and found that they failed to suppress the 
proliferation of CD4+CD25- T cells, and pretreatment with dexamethasone and 
IL-2 increased the proportion of CD4+Foxp3+ cells and restored function of 
splenic CD4+CD25+ T cells and inhibited development of EAE (Xin Chen 2006). 
The implications of this study are that the combination of glucocorticoids and IL-2 
could provide a novel approach for GVHD treatment or the treatment of 
autoimmune diseases. For the purposes of our project, this paper actually was 
not able to show that glucocorticoid treatment alone increased the amount of 
Treg- however the implications of this study may be clinically relevant.  
 Glucocorticoids were found to increase Foxp3 expression of regulatory T 
cells in patients affected by asthma. In a study by Karagiannidis et al, CD4+ T 
cells from healthy donors, and glucocorticoid treated asthma patients were 
isolated and their expression of Foxp3, IL-10, and TGF-β was determined 
(Karagiannidis 2004). They found that Foxp3 mRNA expression was significantly 
increased in asthmatic patients receiving inhaled glucocorticoid treatment, 
systemic glucocorticoid treatment, or both.  
 Glucocorticoids were also shown to restore the impaired suppressive 
function of regulatory T cells in patients with relapsing multiple sclerosis. In a 
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study by Xu et al, 14 patients relapsing from multiple sclerosis were treated with 
high dose IV injection of glucocorticoid, the effects of GC treatment on Treg 
function were evaluated ex vivo and in vitro compared to 20 healthy controls. 
Treg function was significantly enhanced after 5 days of GC treatment, and there 
was a trend towards increasing CD4+CD25+Foxp3+ T cells and IL-10 secretion 
with GC treatment when compared to healthy controls (Xu 2009).  
 A similar prospective study done on seventeen patients with active 
systemic lupus erythematosus found that patients taking oral prednisone had an 
increased proportion of circulating regulatory T cells than those who were not. 
This study found that high intravenous dose of methylprednisolone induces a 
rapid, transient increase in circulating Tregs, which may be an important part of 
methylprednisolone’s preventive effect on subsequent flares in systemic lupus 
erythematosus (Mathian 2015).  
 While these papers show the positive effect of steroids on Tregs in the 
presence of autoimmune diseases, there is limited data on the effect of 
glucocorticoids on Tregs in the context of solid organ transplantation. Because 
steroid treatment causes various side effects, there have been many clinical 
efforts to minimize glucocorticoid therapy in transplant patients and it has actually 
been demonstrated that low dose IV methylprednisolone therapy has the same 
effect on renal graft rejection outcomes as high dose IV treatment. Seissler’s 
study examines the effect of low dose methylprenisolone on the composition of 
the Treg population in renal transplant patients. This study found that 
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methylprenisolone has the ability to enhance the suppressive activity of the Treg 
pool by increasing the percentage of highly differentiated and highly suppressive 
HLA-DRhighCD45RA- Tregs (Seissler 2012).  
 One paper tried to investigate the possible mechanism by which 
glucocorticoids increase Treg cell frequency. They investigated glucocorticoid-
induced leucine zipper (GILZ), which is a protein induced by glucocorticoids, 
which promotes Treg cell production. They found that in mice, overexpression of 
GILZ increased the number of regulatory T cells, while deficiency of GILZ 
impaired the generation of peripheral regulatory T cells associated with 
inflammation. This study discovered that GILZ is required in order for 
glucocorticoids to induce TGF-β and Foxp3, and it also enhances TGF-β 
signaling by binding to and promoting Smad2 phosphorylation and activating 
Foxp3 expression. The results of this study established a link between the GILZ 
mechanism and the TGF-β dependent Treg cell production by glucocortiocids 
(Bereshchenko 2014).  
 Finally in regards to the effects of glucocorticosteroids on skin, Stary et al. 
performed a study whereby nickel allergic patients were exposed to nickel for 48 
hours followed by treatment with 40mg of prednisone for 10 days . This was done 
twice, with 30 days separating the two epidermal patch tests, and skin was 
assessed each time. After the second epidermal patch test, the prednisone group 
had reduced skin inflammation and had higher frequency of Foxp3 (Stary 2011). 
It was established that this response was Foxp3 specific because there was no 
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increased frequency of CD45, a generic leukocyte marker, in the treatment group 
post treatment with prednisone.  
 While these studies shine light on potential mechanisms by which 
glucocorticosteroids suppress an immune response, it remains important to 
elucidate their association with Tregs, especially in the context of graft versus 




  The purpose of this thesis is to understand T cell chimerism in the skin 
during and after resolution of acute GVHD. The first aim was to compare T cell 
chimerism in the skin during and after resolution of acute GVHD. The second aim 
was to investigate the effect of systemic steroids on host versus donor T cell 






















  Subjects were selected from a database of adult male patients 
transplanted with female donor cells who underwent skin biopsy for acute GVHD 
at Brigham and Women’s Hospital/Dana Farber Cancer Institute. Medical records 
were reviewed to confirm that each patient was diagnosed clinically with acute 
skin GVHD, and each patient’s skin biopsy was read by an experienced 
dermatopathologist as consistent with GVHD. Samples from any patients with 
underlying T cell malignancy, history of prior transplant, or with limited available 
tissue sample were excluded.   
Patients underwent skin biopsies for clinical purposes. As such, biopsies 
were obtained at variable time points after disease onset, so some biopsies were 
collected after initiation of systemic immunosuppression. In addition, 5 patients 
underwent additional skin biopsy for unrelated clinical reason (no active skin 
GVHD) after their acute skin GVHD had resolved.  
 Patient medical record data were collected including age, underlying 
diagnosis, timing between transplant and treatment, time (if any) between 
treatment and biopsy, prior therapies, conditioning regimen, GVHD prophylaxis, 
and GVHD treatment. Pathology reports were also read from each biopsy. This 





Fluorescence in situ hybridization-Immunofluorescence (FISH-IF) on FFPE 
tissue 
 FFPE skin sections 5-6 micrometers thick were baked, deparaffinized, 
rehydrated, and treated with sodium citrate 10mM pH 6 antigen retrieval buffer 
for 30 minutes at 96 degrees Celsius, then treated with pepsin. FISH probes for 
X and Y chromosomes (Abbott Molecular) were hybridized overnight at 37 
degrees Celsius, requiring denaturation at 94 degrees Celsius prior to 
hybridization. Skin sections were washed after hybridization and then blocked for 
non-specific protein binding. The skin sections were then stained for mouse anti-
human CD3 (Leica), then with anti-mouse IgG AF647 (ThermoFisher Scientific). 
All sections were counterstained with DAPI. A Mantra Quantitative Pathology 
Workstation was used to image the tissue and InFORM software (PerkinElmer) 
was used for analysis.  
 
Quantification of Percentage T Cell Chimerism 
 Images were taken from multiple high-power fields (defined as an image 
taken at 400x) of each patient sample using the Mantra imaging system. Using 
the Inform analysis software, total T cells were manually identified and counted 
based on the CD3 T cell marker. Of the CD3 positive cells, the number of female 
or male T cells was manually counted based on the presence of a Y 
chromosome stain or two X chromosome stains. If the stain was not clear 
enough to be determined, it was not counted as identifiable. Of the identifiable 
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cells, the percentage of male and female cells was calculated for each image and 
then averaged for all the images taken for each patient sample. The percentage 
of host T cells from the biopsies during acute GVHD was compared to the 
percentage of host T cells from the biopsies of post-GVHD skin.  
 
Immunofluorescence 
 FFPE skin samples were baked, deparaffinized, rehydrated, then exposed 
to Tris EDTA pH 9 antigen retrieval buffer at 96 degrees Celsius for 50 minutes, 
and were blocked for non-specific protein binding with TBS + 5% Normal Donkey 
Serum. An antibody panel was created and optimized to stain for regulatory T 
cells against CD3, CD4, and Foxp3 markers. We used rabbit IgG CD4 (Epitomics 
Ep204, 1:100 dilution), Rat IgG1 CD3 (BioRad CD3-12, 1:200 dilution), and 
mouse IgG1k Foxp3 (EBioscience 206D, 1:50 dilution) as our primary antibodies, 
and then applied donkey anti-rabbit IgG AF 488 (Invitrogen R37118, 1:500 
dilution), donkey anti-rat IgG AF 594 (Invitrogen A-21209, 1:500 dilution), and 
donkey anti-mouse IgG AF 647 (Invitrogen A-31571, 1:200 dilution). The optimal 
dilutions were experimentally determined. Images were taken using the Mantra 
Imaging System of multiple high-power fields (400x), and frequency and percent 





 GraphPad Prism was used to graph data and perform statistical tests. For 
the Post-GVHD study, a two-tailed paired parametric t-test was done 
(alpha=0.05). For the Treg study, a two tailed unpaired parametric t-test with 






Assessment of T Cell Chimerism in Post-GVHD Skin 
To compare T cell chimerism in skin during acute GVHD to post-GVHD 
skin, we identified five patients who had skin biopsies taken and available for 
analysis at both points. The clinical characteristics of these patients are detailed 
in Table 1. Most patients had underlying diagnoses different from one another, 
other than two with acute myeloid leukemia. Prior treatments were variable 
across all five patients. Conditioning regimens, GVHD prophylaxis, and GVHD 
treatment were similar but not equal in all patients, and timing between biopsies 
was dependent on the patients’ clinical presentation so they were all different 
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Table 1. Patient characteristic table for comparing active GVHD chimerism 
to post-GVHD (Cohort 1) 
1 
                                                 
1 ATG= anti-thymocyte globulin; MTX=methotrexate; CML=chronic myeloid leukemia; 
CVAPL/ASP=cyclophosphamide/cytarabine, vincristine, prednisone, L-asparaginase, 6-
MP=mercaptopurine; AML= acute myeloid leukemia; AraC= cytarabine; NHL= non-hodgkins lymphoma; 
CVP-R= rituximab, cyclophosphamide, vincristine sulfate, and prednisone; RICE= rituximab, ifosfamine, 
carboplatin, etoposide; AMD-3100= plerixafor; R-CHOP=rituximab, cyclophosphamide, 
hydroxydaunomycin, oncovin, prednisone; MMF=mycophenolate mofetil; AML=acute myeloid leukemia; 
MEC=mitoxantrone, etoposide, cytarabine 
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The following figures illustrate representative images of staining, from 
which the raw data were collected: the total number of CD3+ T cells, CD3+ 
female T cells, and CD3+ male T cells was manually counted from various high-
power fields of view for each patient.  
The red stain is for the X chromosome. When two X chromosomes within 
the same nucleus are clearly seen as prominent red dots spaced apart, as shown 
in figure 2, the T cell can properly be counted as female. Good examples of Y 
staining can also be seen in the following figures. When one Y chromosome is 






Figure 2. Example FISH-IF images for X and Y chromosomes with CD3 
immunofluorescence stain in post-GVHD skin. Yellow=CD3, Green=Y 
chromosome, Red=X chromosome, Blue=DAPI nuclear stain. Imaged at 400x. A) 
Donor (female, 2 X chromosomes) T cells (CD3+) in a male host. B) Two host 
(male, XY) non T cells (CD3-). c) Close-up image of a donor (female, XX) T cell 
(CD3+) adjacent to a host (male, XY) non T cell (CD3-). D) Host and donor T cell. 
While most of the host cells in this study were not T cells, as donor chimerism 




 Upon analysis of the fluorescence in situ hybridization-
immunofluorescence of the post-GVHD samples in comparison to the same 
patients’ biopsies taken during active acute GVHD, we found that there was a 
significant shift among the T cells in skin from host (male) to donor (female) 
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origin for all patients studied. Nearly all (ranging from 95-100%) of the CD3+ T 
cells in the skin that were imaged in post-GVHD skin were of donor origin, 
meaning that they stained for two X chromosomes (female).  
The percentage of host versus donor T cells was calculated by dividing 
the number of female/male CD3+ cells by the total number of “ identifiable” 
(either definitely male or female) CD3 cells. This calculation did not take into 
account any CD3+ cells that were not definitively identifiable as male or female. 
The percentage of host T cells during acute GVHD was then compared to the 








Figure 3. Sparse T cell infiltrate in post-GVHD skin is primarily donor. a-c: 
Yellow=CD3, Green=Y chromosome, Red=X chromosome, Blue=DAPI nuclear 
stain. Images taken at 400x. These three example images show very few T cells 
within patient skin showing that the only T cell present is donor-derived. d: 
Quantification of all five patient samples’ T cell chimerism in skin biopsies during 
active GVHD versus post-GVHD.  
 
  
 Given the dramatic shift from mixed chimerism to nearly 100% donor T 
cells in skin after disease resolution, we wondered whether this was the natural 
consequence of mixed chimerism and active GVHD or a result of treatment. To 
address this, we studied patients with severe acute GVHD (stages 3 and 4), nine 
of whom received systemic steroid treatment prior to biopsy, and six who had 
not. Of these, we were able to stain five patient samples from each group. (Table 
2). They had various underlying diagnoses, such as AML, CML, CLL, and 
lymphoma. There was a good distribution between myeloablative and non-
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myeloablative HSCT, and most of the patients received similar GVHD 
prophylaxis.  
 
Table 2. Patient characteristic table in treatment versus no treatment cohort   
Clinical Parameters GVHD Treatment Cohort GVHD Non-Treatment Cohort 
No. of Patients 5 5 
Age, median (range)  41 (23-60) 54 (33-59) 
Underlying Diagnosis AML(n=2), CML, CLL, MDS 
 
Follicular Lymphoma(n=3) 
MDS (post Hodgkins tx) 
AML 
Conditioning   
Myeloablative, n (%) 
Non-Myeloablative, n (%) 






MHC allele match/ mismatch   
Matched, n (%) 





Relationship Status   
Related, n (%) 





GVHD Prophylaxis 4x Tacrolimus + MTX 
1x 4x Tacrolimus + Sirolimus MTX 
 
2x Sirolimus + MMF 
1x Tacrolimus + MTX 
1x Tacrolimus + MTX+Velcade 
1x Tacrolimus + Sirolimus 
 
 
T cell chimerism in skin in treatment and non-treatment groups 
Quantification using FISH-IF revealed that the percentage of host T cells was 
lower in skin of patients who had received systemic steroids prior to biopsy 
raising the question of whether steroids caused host T cells to die off (Figure 4a). 
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However quantification of total host T cell numbers per high-powered field 
showed that the number was not significantly reduced in the treatment group 
(Figure 4b). Rather, the total number of T cells per high-powered field was 
actually increased, as was the total number of donor T cells in the treatment 






Figure 4. Effect of systemic steroid treatment on host versus donor T cell 
chimerism. a) The percentage of host T cells is higher for the non-treatment 
group. b) There is no significant difference in number of host T cells between the 
treatment and non-treatment group. c) There is no significant difference in the 
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total number of T cells per high power field between the treatment and non-
treatment group. d) There is a significant increase in the number of donor T cells 
in the treatment group. This is notable especially because there is no 
corresponding increase in the number of host T cells.  
This data suggested that donor T cells were recruited into the skin by systemic 
steroids and were actually mitigating disease. Donor T cells could theoretically 
resolve GVHD if they were Treg that suppressed the immune response or 
possibly if they were effector cells that destroyed host T cells, and the absence of 
host T cells reduced the stimulus for disease. To address this, available patient 
samples from treatment and non-treatment groups were stained for CD3, CD4, 
and Foxp3, and the frequency and percentage of Treg was quantified (Figure 5). 
There was no difference between either the percentage of Treg per HPF or the 
frequency of Treg per high-powered field suggesting that donor Treg are not the 




Figure 5. There is no difference in percentage and frequency of Treg 
between the treatment and non-treatment group. A) Graph showing 
percentage of CD3+ T cells that are CD4+Foxp3+ (Treg). B) Frequency of 
















 Most studies on chimerism after hematopoietic stem cell transplantation 
are done in blood. Studies on chimerism in peripheral tissues such as skin are 
much less common though extremely important especially in the context of graft 
versus host disease. This could be because it is more difficult to obtain biopsies 
of the peripheral tissues, especially from the same patients at various time points 
throughout their course of disease. We were able to do this with our retrospective 
patient samples and successfully study T cell chimerism in acute skin GVHD 
during and after resolution of GVHD. One limitation of this study, however, is that 
the biopsies taken post-GVHD were taken for other clinical purposes, i.e. active 
skin issues, rather than truly healthy skin. Despite the reason for the post-GVHD 
skin biopsy, all five patients clearly had a signficant shift toward donor T cells.  
 In blood, mixed chimerism, compared to complete donor chimerism, has 
been significantly associated with decreased risk of GVHD (Mattsson 2001).  
Frassoni et al also found that GVHD risk was significantly higher in patients with 
complete chimerism compared to mixed chimeras. These papers show that in 
blood, mixed chimerism is important for the development of tolerance. However, 
as has been identified by Divito et al, chimerism in the peripheral tissues does 
not reflect that in the blood, and our data suggest that mixed chimerism may 
promote GVHD. 
The shift we observed in T cell chimerism in resolved GVHD skin led us to 
ask whether this was a natural result of GVHD or potentially a result of treatment 
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interventions. Analysis of treated versus non-treated groups support that in fact 
treatment results in a shift to donor T cell chimerism in skin, by recruiting in donor 
T cells, rather than by a direct loss of host T cells.  
We performed our next study in part to identify what types of donor T cells 
are involved in the resolution of severe acute GVHD, hypothesizing that donor 
Tregs play a role and are recruited by the systemic steroid treatment that these 
patients received. Our results from this study, however, did not show a difference 
between the frequency or percentage of Tregs between treatment and non-
treatment groups. It is possible that with a higher n value, a significant difference 
might be observed. Additionally, staining of additional skin sections would 
increase total number of T cells available for analysis and potentially reveal a 
difference between groups. Another limitation at the current phase of this study is 
that we were unable to retrieve all the relevant treatment information from the 
online medical records of these patients. This impedes our ability to make 
conclusions about the timing of the treatment in relation to the biopsy- for 
example, if treated immediately before biopsy, perhaps the treatment did not 
have time to take effect. Additionally, it is extremely important to take into 
consideration the dosage of the steroids given and the number of treatments 
received before biopsy. If possible, we will try to obtain this information so that 
conclusions can properly be made about the findings from this cohort of patients.  
It is also possible that Foxp3 negative regulatory T cells are being 
recruited by the treatment, which we would not have identified using our staining 
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panel. It is now known that a Foxp3 negative population of regulatory T cells 
possess immunosuppressive properties. IL-10 was found to drive the generation 
of a subset of CD4+ regulatory T cells that suppress antigen-specific immune 
responses and downregulate a pathological immune response in vivo (Groux 
1997). Zohar et al found that the induction of Foxp3 negative Treg cells 
suppresses autoimmune encephalomyelitis through binding of the CXCL11-
chemokine. This immunotolerized state is characterized by IL-10 and IL-4 high 
cells. One thing notable about this study is that CXCL11 upregulated IL-10 only 
in Foxp3- T cells. It is therefore possible that systemic steroids could be 
promoting this unique Treg subset (Foxp3- IL-10 producing Tregs). Future work 
therefore is to stain tissue sections for CD3, CD4 and IL-10 to address this.  
Finally, it is possible that the donor T cells recruited into skin as a result of 
systemic steroids are not regulatory at all, but in fact effector T cells that are 
directly targeting and eliminating host T cells. This would suggest the possibility 
that it is the presence of mixed chimerism that stimulates GVHD. We are 




 The concept that host T cells survive and participate in acute GVHD is a 
novel one (Divito 2020, recently accepted for publication), and ours is the first 
study to interrogate better the presence and role of host versus donor T cells in 
GVHD resolution. Through retrospective FISH-IF studies, a dramatic shift toward 
donor T cell chimerism was observed in the skin after resolution of acute GVHD. 
Likewise, a significant increase in the number of donor T cells in a group of 
severe acute GVHD patients who received systemic steroid treatment at the time 
of biopsy compared to those who did not was seen, suggesting that treatment 
hastens disease resolution through recruitment of donor T cells. We are currently 
following up our results with further investigation into the effects of systemic 
steroids on the types of donor T cells recruited to skin (regulatory versus effector) 
and their interaction with host T cells. This study therefore has major implications 
for not only our understanding of the pathobiology of GVHD but for treatment 
approaches in the clinic.  












LIST OF JOURNAL ABBREVIATIONS 
J Immunol=Journal of Immunology  
Nat Med= Nature Medicine 







Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host 
disease after HLA-identical sibling bone marrow transplantation. Blood. 
1990;75(12):2459-2464. https://pubmed.ncbi.nlm.nih.gov/2350582. 
Ball LM, Egeler RM, on behalf of the EBMT Paediatric, Working Party. Acute GvHD: 
Pathogenesis and classification. Bone Marrow Transplant. 2008;41(2):S58-
S64. https://doi.org/10.1038/bmt.2008.56. doi: 10.1038/bmt.2008.56. 
Beres, A. J., & Drobyski, W. R. (2013). The Role of Regulatory T Cells in the Biology 
of Graft Versus Host Disease. Frontiers in Immunology, 4(JUN), 163. 
https://doi.org/10.3389/fimmu.2013.00163 
Bereshchenko O, Coppo M, Bruscoli S, et al. GILZ promotes production of 
peripherally induced treg cells and mediates the crosstalk between 
glucocorticoids and TGF-β signaling. Cell reports. 2014;7(2):464-
475. https://pubmed.ncbi.nlm.nih.gov/24703841. doi: 
10.1016/j.celrep.2014.03.004. 
Blazar, B. R., Murphy, W. J., & Abedi, M. (2012). Advances in graft-versus-host 
disease biology and therapy. In Nature Reviews Immunology (Vol. 12, Issue 6, 
pp. 443–458). https://doi.org/10.1038/nri3212 
Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS. In 
vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with 





mc/articles/PMC2637199/. doi: 10.1182/blood-2008-06-162420. 
Chen, Xiao, Vodanovic-Jankovic, S., Johnson, B., Keller, M., Komorowski, R., & 
Drobyski, W. R. (2007). Absence of regulatory T-cell control of TH1 and TH17 
cells is responsible for the autoimmune-mediated pathology in chronic graft-
versus-host disease. Blood, 110(10), 3804–3813. https://doi.org/10.1182/blood-
2007-05-091074 
Chen, Xin, & Oppenheim, J. J. (2011). Resolving the identity myth: Key markers of 
functional CD4 +FoxP3 + regulatory T cells. In International 
Immunopharmacology (Vol. 11, Issue 10, pp. 1489–1496). 
https://doi.org/10.1016/j.intimp.2011.05.018 
Chen, Xin, Oppenheim, J. J., Winkler-Pickett, R. T., Ortaldo, J. R., & Howard, O. M. 
Z. (2006). Glucocorticoid amplifies IL-2-dependent expansion of functional 
FoxP3+CD4+CD25+ T regulatory cells in vivo and enhances their capacity to 
suppress EAE. European Journal of Immunology, 36(8), 2139–2149. 
https://doi.org/10.1002/eji.200635873 
Choi SW, Islam S, Greenson JK, et al. The use of laparoscopic liver biopsies in 
pediatric patients with hepatic dysfunction following allogeneic hematopoietic 
stem cell transplantation. Bone Marrow Transplant. 2005;36(10):891-
896. https://doi.org/10.1038/sj.bmt.1705158. doi: 10.1038/sj.bmt.1705158. 
 
39 
Corthay, A. (2009). How do regulatory t cells work? In Scandinavian Journal of 
Immunology (Vol. 70, Issue 4, pp. 326–336). https://doi.org/10.1111/j.1365-
3083.2009.02308.x 
Devaud, C., Darcy, P. K., & Kershaw, M. H. (2014). Foxp3 expression in T regulatory 
cells and other cell lineages. Cancer Immunology, Immunotherapy, 63(9), 869–
876. https://doi.org/10.1007/s00262-014-1581-4 
Divito SJ, Elco C, Guleria I, Milford E, Cutler C, Kupper TS. Host skin T cells survive 




Ferrara, J. L., Levine, J. E., Reddy, P., & Holler, E. (2009). Graft-versus-host disease. 
In The Lancet (Vol. 373, Issue 9674, pp. 1550–1561). 
https://doi.org/10.1016/S0140-6736(09)60237-3 
Filipovich, A. H., Weisdorf, D., Pavletic, S., Socie, G., Wingard, J. R., Lee, S. J., 
Martin, P., Chien, J., Przepiorka, D., Couriel, D., Cowen, E. W., Dinndorf, P., 
Farrell, A., Hartzman, R., Henslee-Downey, J., Jacobsohn, D., McDonald, G., 
Mittleman, B., Rizzo, J. D., … Flowers, M. E. D. (2005). National Institutes of 
Health Consensus Development Project on criteria for clinical trials in chronic 
graft-versus-host disease: I. diagnosis and staging working group report. In 




Frassoni, F., Strada, P., Sessarego, M., Miceli, S., Corvò, R., Scarpati, D., Vitale, V., 
Piaggio, G., Raffo, M. R., & Sogno, G. (1990). Mixed chimerism after allogeneic 
marrow transplantation for leukaemia: correlation with dose of total body 
irradiation and graft-versus-host disease. Bone Marrow Transplantation, 5(4), 
235–240. http://www.ncbi.nlm.nih.gov/pubmed/2186836 
Glucksberg, H., Storb, R., Fefer, A., Buckner, C. D., Neiman, P. E., Clift, R. A., 
Lerner, K. G., & Thomas, E. D. (1974). Clinical manifestations of graft-versus-
host disease in human recipients of marrow from hl-a-matched sibling donors1. 
Transplantation, 18(4), 295–304. https://doi.org/10.1097/00007890-197410000-
00001 
Griffith, L. M., Cowan, M. J., Kohn, D. B., Notarangelo, L. D., Puck, J. M., Schultz, K. 
R., Buckley, R. H., Eapen, M., Kamani, N. R., O’Reilly, R. J., Parkman, R., 
Roifman, C. M., Sullivan, K. E., Filipovich, A. H., Fleisher, T. A., & Shearer, W. T. 
(2008). Allogeneic hematopoietic cell transplantation for primary immune 
deficiency diseases: Current status and critical needs. Journal of Allergy and 
Clinical Immunology, 122(6), 1087–1096. 
https://doi.org/10.1016/j.jaci.2008.09.045 
Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-
cell responses and prevents colitis. Nature. 1997;389(6652):737-
742. https://pubmed.ncbi.nlm.nih.gov/9338786. doi: 10.1038/39614. 
 
41 
Henden AS, Hill GR. Cytokines in graft-versus-host disease. J Immunol. 
2015;194(10):4604. http://www.jimmunol.org/content/194/10/4604.abstract. doi: 
10.4049/jimmunol.1500117. 
Hess, A. D. (2006). Modulation of graft-versus-host disease: Role of regulatory T 
lymphocytes. Biology of Blood and Marrow Transplantation, 12(1 SUPPL. 2), 13–
21. https://doi.org/10.1016/j.bbmt.2005.11.002 
Hoffmann, P., Ermann, J., Edinger, M., Garrison Fathman, C., & Strober, S. (2002). 
Donor-type CD4+CD25+ regulatory T cells suppress lethal acute graft-versus-
host disease after allogeneic bone marrow transplantation. Journal of 
Experimental Medicine, 196(3), 389–399. https://doi.org/10.1084/jem.20020399 
Jagasia, M. H., Greinix, H. T., Arora, M., Williams, K. M., Wolff, D., Cowen, E. W., 
Palmer, J., Weisdorf, D., Treister, N. S., Cheng, G. S., Kerr, H., Stratton, P., 
Duarte, R. F., McDonald, G. B., Inamoto, Y., Vigorito, A., Arai, S., Datiles, M. B., 
Jacobsohn, D., … Flowers, M. E. D. (2015). National Institutes of Health 
Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-
versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. 
Biology of Blood and Marrow Transplantation, 21(3), 389-401.e1. 
https://doi.org/10.1016/j.bbmt.2014.12.001 
Jamil, M. O., & Mineishi, S. (2015). State-of-the-art acute and chronic GVHD 
treatment. In International Journal of Hematology (Vol. 101, Issue 5, pp. 452–
466). Springer-Verlag Tokyo. https://doi.org/10.1007/s12185-015-1785-1 
 
42 
Karagiannidis, C., Akdis, M., Holopainen, P., Woolley, N. J., Hense, G., Rückert, B., 
Mantel, P. Y., Menz, G., Akdis, C. A., Blaser, K., & Schmidt-Weber, C. B. (2004). 
Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. 
Journal of Allergy and Clinical Immunology, 114(6), 1425–1433. 
https://doi.org/10.1016/j.jaci.2004.07.014 
le Texier, L., Lineburg, K. E., & MacDonald, K. P. A. (2017). Harnessing bone marrow 
resident regulatory T cells to improve allogeneic stem cell transplant outcomes. 
In International Journal of Hematology (Vol. 105, Issue 2, pp. 153–161). Springer 
Tokyo. https://doi.org/10.1007/s12185-016-2161-5 
Loiseau P, Busson M, Balere M, et al. HLA association with hematopoietic stem cell 
transplantation outcome: The number of mismatches at HLA-A, -B, -C, -DRB1, or 
-DQB1 is strongly associated with overall survival. Biology of blood and marrow 
transplantation : journal of the American Society for Blood and Marrow 
Transplantation. 2007;13(8):965-974. https://pubmed.ncbi.nlm.nih.gov/17640601. 
doi: 10.1016/j.bbmt.2007.04.010. 
Mathian A, Jouenne R, Chader D, et al. Regulatory T cell responses to high-dose 
methylprednisolone in active systemic lupus erythematosus. PloS one. 
2015;10(12):e0143689. https://pubmed.ncbi.nlm.nih.gov/26629828 https://www.n
cbi.nlm.nih.gov/pmc/articles/PMC4667921/. doi: 10.1371/journal.pone.0143689. 
Mattsson J, Uzunel M, Remberger M, Ringdén O. T cell mixed chimerism is 
significantly correlated to a decreased risk of acute graft-versus-host disease 
after allogeneic stem cell transplantation. Transplantation. 2001;71(3):433-
 
43 
439. https://pubmed.ncbi.nlm.nih.gov/11233907. doi: 10.1097/00007890-
200102150-00017. 
Merad M, Hoffmann P, Ranheim E, et al. Depletion of host langerhans cells before 
transplantation of donor alloreactive T cells prevents skin graft-versus-host 
disease. Nat Med. 2004;10(5):510-517. https://doi.org/10.1038/nm1038. doi: 
10.1038/nm1038. 
Morris, G. P., Uy, G. L., Donermeyer, D., DiPersio, J. F., & Allen, P. M. (2013). Dual 
receptor T cells mediate pathologic alloreactivity in patients with acute graft-
versus-host disease. Science Translational Medicine, 5(188), 188ra74-188ra74. 
https://doi.org/10.1126/scitranslmed.3005452 
Paczesny, S., Hanauer, D., Sun, Y., & Reddy, P. (2010). New perspectives on the 
biology of acute GVHD. In Bone Marrow Transplantation (Vol. 45, Issue 1, pp. 1–
11). https://doi.org/10.1038/bmt.2009.328 
Qayed, M., & T. Horan, J. (2016). The Role of Intestinal Microbiota in Graft versus 
Host Disease. Mini-Reviews in Medicinal Chemistry, 16(3), 193–199. 
https://doi.org/10.2174/1389557515666150722110547 
Rezvani, K., Mielke, S., Ahmadzadeh, M., Kilical, Y., Savani, B. N., Zeilah, J., 
Keyvanfar, K., Montero, A., Hensel, N., Kurlander, R., & Barrett, A. J. (2006). 
High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a 




Schroeder, M. A., & DiPersio, J. F. (2011). Mouse models of graft-versus-host 
disease: Advances and limitations. In DMM Disease Models and Mechanisms 
(Vol. 4, Issue 3, pp. 318–333). https://doi.org/10.1242/dmm.006668 
Seissler N, Schmitt E, Hug F, et al. Methylprednisolone treatment increases the 
proportion of the highly suppressive HLA-DR(+)-treg-cells in transplanted 
patients. Transpl Immunol. 2012;27(4):157-
161. https://pubmed.ncbi.nlm.nih.gov/23022208. doi: 10.1016/j.trim.2012.09.003. 
Snover DC, Weisdorf SA, Ramsay NK, Mcglave P, Kersey JH. Hepatic graft versus 
host disease: A study of the predictive value of liver biopsy in 
diagnosis. Hepatology. 1984;4(1):123-
130. https://doi.org/10.1002/hep.1840040122. doi: 10.1002/hep.1840040122. 
Stary G, Klein I, Bauer W, et al. Glucocorticosteroids modify langerhans cells to 
produce TGF-β and expand regulatory T cells. J Immunol. 
2011;186(1):103. http://www.jimmunol.org/content/186/1/103.abstract. doi: 
10.4049/jimmunol.1002485. 
Teshima, T., Reddy, P., & Zeiser, R. (2016). Acute Graft-versus-Host Disease: Novel 
Biological Insights. In Biology of Blood and Marrow Transplantation (Vol. 22, 
Issue 1, pp. 11–16). Elsevier Inc. https://doi.org/10.1016/j.bbmt.2015.10.001 
Xu L, Xu Z, Xu M. Glucocorticoid treatment restores the impaired suppressive 
function of regulatory T cells in patients with relapsing–remitting multiple 
sclerosis. Clinical & Experimental Immunology. 2009;158(1):26-
 
45 
30. https://doi.org/10.1111/j.1365-2249.2009.03987.x. doi: 10.1111/j.1365-
2249.2009.03987.x. 
Zhang, L., Chu, J., Yu, J., & Wei, W. (2016a). Cellular and molecular mechanisms in 
graft-versus-host disease. Journal of Leukocyte Biology, 99(2), 279–287. 
https://doi.org/10.1189/jlb.4RU0615-254RR 
Zhang, L., Chu, J., Yu, J., & Wei, W. (2016b). Cellular and molecular mechanisms in 
graft-versus-host disease. Journal of Leukocyte Biology, 99(2), 279–287. 
https://doi.org/10.1189/jlb.4ru0615-254rr 
Zohar, Y., Wildbaum, G., Novak, R., Salzman, A. L., Thelen, M., Alon, R., 
Barsheshet, Y., Karp, C. L., & Karin, N. (2014). CXCL11-dependent induction of 
FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. 
Journal of Clinical Investigation, 124(5), 2009–2022. 
https://doi.org/10.1172/JCI71951 
  
  
 
 
 
 
 
 
 
  
 
46 
CURRICULUM VITAE 
 
47 
 
48 
 
49 
